Does the duration of exposure to everolimus influence the occurrence of chronic lung allograft dysfunction?
Transplant Immunology · 2026
DOI: 10.1016/j.trim.2026.102436 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Transplant Immunology, 2026. Verfasst von Agathe Landoas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Grenoble Alpes, Pharmacy Department, Grenoble Alpes University Hospital, Grenoble, France. Hauptthemen laut MEDLINE: Everolimus, Graft Rejection, Immunosuppressive Agents, Lung Transplantation. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Everolimus has been incorporated into the immunosuppressive management of lung transplant patients. Due to its anti-proliferative properties, it is being studied in the context of chronic lung allograft dysfunction (CLAD). This study aims to evaluate the factors involved in the occurrence of CLAD, as well as the effects of introducing everolimus. MATERIALS AND METHODS: A retrospective, single-center observational study was conducted. The population studied consisted of lung transplant patients between January 1, 2000, and August 2021, who were treated with everolimus during their follow-up. Clinical, paraclinical, and biological data were collected from the patients' medical records. RESULTS: The timing of everolimus introduction was identified as a risk factor for CLAD [OR 1.069, 95% CI: 1.017; 1.123], as well as the number of everolimus discontinuations [OR 12.660, 95% CI: 1.025; 156.329]. DISCUSSION: Our study suggests a beneficial role of everolimus in preventing CLAD, particularly when introduced early and with minimal treatment interruptions. Lung function stability was maintained in our lung transplant patients. CONCLUSION: The use of everolimus for the prevention of CLAD is encouraging. This therapeutic class demonstrates effectiveness as well as safety in long-term biological parameter outcomes in lung transplant patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ. Grenoble Alpes, Pharmacy Department, Grenoble Alpes University Hospital, Grenoble, France.
- Univ. Grenoble Alpes, INSERM U1055, Pharmacy Department, LBFA, Grenoble Alpes University Hospital, Grenoble, France. Electronic address: qperrier@chu-grenoble.fr.
- Univ. Grenoble Alpes, Pneumology and Physiology Department, Grenoble Alpes University Hospital, Grenoble, France.
- Univ. Grenoble Alpes, INSERM U1300, Pneumology and Physiology Department, Grenoble Alpes University Hospital, HP2, Grenoble, France.
- Univ. Grenoble Alpes, CNRS, Pharmacy Department, TIMC, UMR5525, Grenoble Alpes University Hospital, Grenoble, France.
Zitieren
APA
Landoas, A., Perrier, Q., Falque, L., Saint-Raymond, C., Briault, A., Degano, B., Chanoine, S., & Bedouch, P. (2026). Does the duration of exposure to everolimus influence the occurrence of chronic lung allograft dysfunction?. Transplant Immunology. https://doi.org/10.1016/j.trim.2026.102436
Vancouver
Landoas A, Perrier Q, Falque L, Saint-Raymond C, Briault A, Degano B, et al. Does the duration of exposure to everolimus influence the occurrence of chronic lung allograft dysfunction?. Transplant Immunology. 2026. doi:10.1016/j.trim.2026.102436
BibTeX
@article{Landoas2026,
author = {Landoas, Agathe and Perrier, Quentin and Falque, Loïc and Saint-Raymond, Christel and Briault, Amandine and Degano, Bruno and Chanoine, Sébastien and Bedouch, Pierrick},
title = {Does the duration of exposure to everolimus influence the occurrence of chronic lung allograft dysfunction?},
journal = {Transplant Immunology},
year = {2026},
doi = {10.1016/j.trim.2026.102436}
}
EUVIMED